Mollalign Hilina, Chala Dawit, Beyene Dereje
TB/HIV Directorate, Ethiopian Public Health Institute, Addis Ababa, Ethiopia.
Department of Microbial, Cellular, and Molecular Biology, Addis Ababa University, Addis Ababa, Ethiopia.
Infect Drug Resist. 2022 Jul 27;15:4037-4046. doi: 10.2147/IDR.S370837. eCollection 2022.
Coronavirus disease 19 (COVID-19) and (MTB) are among the top ongoing health crises globally. Both cause respiratory diseases, and the clinical presentations are similar. There is no summarized information about cases of COVID-19 patients with concomitant TB infection from different settings. Therefore this review aimed to summerize the clinical features and treatment outcomes of coronavirus and tuberculosis co-infected patients.
An electronic search of case reports published between 2020 and 2021 was conducted using Google Scholar, PubMed, Scopus, and ScienceDirect. From eligible reports, data were collected for the selected variables. We analyzed the collected information using SPSS version 27 software. Descriptive statistics were computed for the selected variables.
A total of 83 patient histories were collected from 47 case reports. The majority (80%) of the cases were reported for male patients. The mean age was 42.6 years (3 months to 84 years, SD=17.3). Fever was reported in 80% of cases, followed by cough (73.3%) and hypotension (37.1%). Blood cell parameters revealed lymphopenia (52%), lower hemoglobin (30%), elevated CRP (70%), elevated ferritin (28%), and increased D-dimer (23.4%). Treatment outcome is significantly associated with blood cell count results (-0.044) and a rise in blood inflammatory cytokines(-0.041). The mean days for viral clearance or negative PCR was 23 days (Range 5-82 days) and the overall mean duration of hospitalization was 27 days. The total death rate was 22.4%. Recovery was reported for 76.6% of cases. Survival status (-0.613) and disease severity (-0.68) are not significantly associated with the gender of the participants.
An alteration in blood cell parameters is associated with an unfavorable treatment outcome. There is a higher death rate in COVID-19/TB co-infection. The death is associated with older age, smoking or smoking history, drug abuse, and co-morbidity of non-communicable diseases. Conversely, there is a lower death rate in HIV patients.
新型冠状病毒肺炎（COVID-19）和肺结核（MTB）是全球当前最严重的健康危机之一。两者都会引发呼吸道疾病，且临床表现相似。目前尚无来自不同地区的COVID-19合并结核感染患者病例的汇总信息。因此，本综述旨在总结冠状病毒和结核合并感染患者的临床特征及治疗结果。
使用谷歌学术、PubMed、Scopus和ScienceDirect对2020年至2021年发表的病例报告进行电子检索。从符合条件的报告中，收集选定变量的数据。我们使用SPSS 27版软件对收集到的信息进行分析。对选定变量进行描述性统计。
共从47篇病例报告中收集了83份患者病史。大多数病例（80%）为男性患者。平均年龄为42.6岁（3个月至84岁，标准差=17.3）。80%的病例有发热症状，其次是咳嗽（73.3%）和低血压（37.1%）。血细胞参数显示淋巴细胞减少（52%）、血红蛋白降低（30%）、C反应蛋白升高（70%）、铁蛋白升高（28%）和D-二聚体升高（23.4%）。治疗结果与血细胞计数结果（-0.044）和血液炎症细胞因子升高（-0.041）显著相关。病毒清除或PCR阴性的平均天数为23天（范围5 - 82天），总体平均住院时间为27天。总死亡率为22.4%。76.6%的病例报告康复。生存状况（-0.613）和疾病严重程度（-0.68）与参与者的性别无显著关联。
血细胞参数改变与不良治疗结果相关。COVID-19/结核合并感染的死亡率较高。死亡与年龄较大、吸烟或吸烟史、药物滥用以及非传染性疾病合并症有关。相反，HIV患者的死亡率较低。
